08:01 AM EDT, 10/08/2024 (MT Newswires) -- GSK (GSK) said Tuesday that Arexvy, the company's respiratory syncytial virus or RSV vaccine, demonstrated sustained efficacy in the AReSVi-006 Phase 3 trial over three RSV seasons in adults aged 60 and older.

After a single dose, Arexvy showed cumulative efficacy of 62.9% against lower respiratory tract disease, or LRTD, caused by RSV and 67.4% against severe RSV-LRTD, GSK said. The trial also found a 48.0% efficacy against RSV-LRTD in the third season, it added.

GSK noted that the vaccine's safety profile remained consistent with previous findings.

GSK shares lost 1% in recent premarket activity.

Price: 38.24, Change: -0.39, Percent Change: -1.01